Pancreatic Cancer Research

ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years

Hai Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6693-1770; OpenAlex author ID A5073231767. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper

Papers 11

  1. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Co-author DOI 10.1038/s41420-024-01890-y↗
  2. Mitoxantrone and Mitoxantrone-Loaded Iron Oxide Nanoparticles Induce Cell Death in Human Pancreatic Ductal Adenocarcinoma Cell Spheroids. Co-author DOI 10.3390/ma16072906↗
  3. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02443-w↗
  4. An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer. Co-author DOI 10.3389/fcell.2022.975684↗
  5. Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/cancers14133152↗
  6. Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. Co-author DOI 10.3390/cancers15010241↗
  7. CRISPR Cas9 in Pancreatic Cancer Research. Co-author DOI 10.3389/fcell.2019.00239↗
  8. Chemoresistance in Pancreatic Cancer. Last author DOI 10.3390/ijms20184504↗
  9. Identification of Prognostic Biomarkers by Combined mRNA and miRNA Expression Microarray Analysis in Pancreatic Cancer. First author DOI 10.1016/j.tranon.2018.03.003↗
  10. The Effect of GPRC5a on the Proliferation, Migration Ability, Chemotherapy Resistance, and Phosphorylation of GSK-3β in Pancreatic Cancer. First author DOI 10.3390/ijms19071870↗
  11. The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation. First author DOI 10.1371/journal.pone.0170390↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christian P. Pilarsky · 11 shared papers, 2017–2024 · strength 1.46
  2. Robert Grützmann · 8 shared papers, 2017–2024 · strength 1.00
  3. Nathalie Britzen‐Laurent · 5 shared papers, 2022–2024 · strength 0.73
  4. Bin Liu · 4 shared papers, 2017–2022 · strength 0.41
  5. Bin Lan · 3 shared papers, 2019–2024 · strength 0.39
  6. Duo Yun · 2 shared papers, 2022–2024 · strength 0.31
  7. Hang He · 2 shared papers, 2022–2024 · strength 0.30
  8. Peter J. Bailey · 2 shared papers, 2019–2022 · strength 0.29
  9. Shuman Zhang · 2 shared papers, 2022–2024 · strength 0.27
  10. Debabrata Mukhopadhyay · 2 shared papers, 2022–2024 · strength 0.27
  11. Andrew Victor Biankin · 2 shared papers, 2022–2024 · strength 0.27
  12. Siyuan Zeng · 2 shared papers, 2019–2022 · strength 0.24
  13. Stefan Lyer · 1 shared paper, 2023 · strength 0.18
  14. Harald Mangge · 1 shared paper, 2023 · strength 0.18
  15. Jonas Dinter · 1 shared paper, 2023 · strength 0.18
  16. Axel Denz · 2 shared papers, 2017–2018 · strength 0.16
  17. Deliang Fu · 1 shared paper, 2022 · strength 0.15
  18. Yanxi Lu · 1 shared paper, 2024 · strength 0.15
  19. Jinping Zhang · 1 shared paper, 2024 · strength 0.15
  20. Eva Lentsch · 1 shared paper, 2024 · strength 0.15
  21. Marc P. Stemmler · 1 shared paper, 2024 · strength 0.15
  22. Hao Yang · 1 shared paper, 2024 · strength 0.15
  23. Daniel Schreyer · 1 shared paper, 2022 · strength 0.13
  24. David Kuang-Fu Chang · 1 shared paper, 2022 · strength 0.13
  25. Georg F. Weber · 1 shared paper, 2018 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.